In the second group (prophylactic pharmacological CCR4 inhibition before tumor implantation), antagonization of CCR4 significantly decelerated tumor growth (106.0 ± 20.5 mm3) compared to the vehicle control group (129.8 ± 35.1 mm3) (p = 0.317) after 3 weeks. This evidence concerns the gene CCR4 and neoplasm.